U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO
Molecular Weight 137.179
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMOXYPINE

SMILES

CCC1=NC(C)=CC=C1O

InChI

InChIKey=JPGDYIGSCHWQCC-UHFFFAOYSA-N
InChI=1S/C8H11NO/c1-3-7-8(10)5-4-6(2)9-7/h4-5,10H,3H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C8H11NO
Molecular Weight 137.179
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Emoxypine (ethylmethylhydroxypyridine) succinate (MEXIDOL®) is a 3-hydroxypyridine derivative which is quite similar in structure to Vitamin B6 (pyridoxine). The most important components of the mechanism of action of Mexidol® are its antioxidant and membranotropic effects, the ability to modulate functioning of receptors and membrane-bound enzymes, restore a neurotransmitter balance. Due to its mechanism of action Mexidol® has a wide range of pharmacological effects, realized on at least two levels – neuronal and vascular. It has antihypoxic, anti-ischemic, neuroprotective, nootropic, vegetotrophic, anti-stress, anxiolytic, anticonvulsant, anti-alcohol, cardioprotective, anti-atherogenic, geroprotective and other actions. Under the action of Mexidol®, it is observed an improvement in cerebral circulation and microcirculation. Emoxypine is distributed in Russia but it is widely unknown in other regions.

Originator

Curator's Comment: In early 1980s, in State Institution Research Institute of Pharmacology of RAMS, by L.D. Smirnov and V.I. Kuzmin, 2-ethyl-6-methyl-3-hydroxypyridine succinate was synthesized, and under supervision of Academician of RAMS A.V. Valdman, its pharmacological effects were found, the mechanism of action was studied, preclinical studies on toxicology and pharmacokinetics were carried out, the Mexidol® trademark was identified, the drug was registered in the USSR Ministry of Healthcare, the first clinical trials and introduction of the preparation into medical practice were carried out.

Approval Year

PubMed

PubMed

TitleDatePubMed
[Experience with complex treatment for childhood amblyopia].
2008-03-06
[Pharmacological correction of neuronal damage in sensomotor zone of frontal cortex under conditions of experimental cerebral blood flow pathology].
2008-03-06
[The regulatory effect of mexidol on the hemoglobin level under acute stress conditions].
2007-12-14
[Acute radiation sickness in experiment. Efficacy of mexidol].
2007-10-13
[Effect of mexidol on hemopoietic system in conditions of an emotional stress after exposure to ionizing radiation].
2007-06-19
Efficacy of neuroprotectors in patients with tension headaches.
2007-06
[Combined action of mexidol and non-narcotic analgesics on pain thresholds and emotional stress behavior in animals].
2007-05-26
[The effect of rubomycin, mexidol and emoxypine on some metabolic indexes and the proccess of spontaneous metastasis under conditions of experimental neoplasia].
2007-04-04
Lymphotropic effect of dimephosphon, mexidol, and ketorolac is realized via activation of the lymphangion and stimulation of lymph formation.
2007-04
[The efficacy of oxynicotinic acid a nd its derivatives in respect of functional activity of hepatocytes during acute toxic hepatopathy].
2007-02-16
[The effectiveness of ascorbic acid and emoxipin in treatment of infiltrative pulmonary tuberculosis].
2007
[The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents].
2007
[Influence of gel Metrogil Denta and curative toothpaste Mexidol Dent activ on indices of parodontal status and lipid peroxidation in patients with chronic generalized catarrhal gingivitis].
2007
[The influence of 3-oxypyridine antioxidants on depression in patients with diabetes mellitus].
2007
Effect of mexidol and nitroglycerine on iron-sulfur centers, cytochrome P-450, and nitric oxide formation in liver tissue of experimental animals.
2006-10
[Antistressor and analgesic effects of mexidol, diazepam, paracetamol, and their combinations].
2006-09-26
[Antioxidant activity of inhibitors of free radical reactions in the dressing materials for wound healing].
2006-06-03
[The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke].
2006
[Efficacy of the use of antioxidant preparation mexidol in comprehensive treatment of inflammatory diseases of parodontium].
2006
[The use of mexidol in urgent treatment of drug addiction].
2006
[Mexidol in combined treatment of acute pancreatitis].
2006
[Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy].
2006
[Lipid reducing and antioxidant action of mexicor in patients with diabetes mellitus type 2].
2006
[Antioxidants in complex treatment of Parkinson's disease].
2006
[Neurometabolic therapy of diabetic neuropathy].
2006
[Complex therapy of acute and exacerbated chronic nonspecific parotitis including mexidol and non-coherent infrared therapy].
2006
[The use of mexidol in psychiatric practice].
2006
[Neureprotective drugs efficiency in patients with chronic tension headaches].
2006
[Antihypoxant activity and mechanisms of action of some natural and synthetic compounds].
2005-11-10
[Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis].
2005-11-10
[A comparative study of the development of drug differentiation between mexidol and phenazepam].
2005-11-10
Lymphotropic effect of mexidol in reactive fever.
2005-10
Activity of nitric oxide synthase and concentration of nitric oxide end metabolites in the gingiva under experimental pathological conditions.
2005-10
[Study of antiradical activity of new compounds by chemiluminescence].
2005-08-18
[Metabolic effects of mexidole during cardiosurgical operations using extracorporeal circulation].
2005-08-04
[Mexidol corrects model post-reanimation changes in cerebral lipid metabolism].
2005-07-29
[Biotransformation of mexidol in inbred BALB/C and C57BL/6 mice].
2005-06-07
[Efficiency of mexidol during perinatal encephalopathy in early age children].
2005-06
[Antinecrotic and antiischemic effect of mexidol and trental in ischemia of the skin graft].
2005-05
[Mexidol in treatment of children with generalized epilepsy and febrile seizures].
2005-05
The effects of Mexidol on the acquisition of food-related conditioned reflexes and synaptic ultrastructure in field CA1 of the rat hippocampus after single acoustic stimuli with ultrasonic components.
2005-05
Antihypoxic and antinecrotic effect of mexidol in skin ischemia.
2005-02
[Protective effect of activators of biological oxidation in nitrite intoxication in rats].
2005
[The treatment of patients with toxic encephalopathy caused by using surrogate psychoactive manganese-containing compounds].
2005
[Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia].
2005
[Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome].
2005
[Methodological bases of early psychosocial rehabilitation of poststroke patients in neurological hospital].
2005
[Effect of mexicor on oxidative stress in acute myocardial infarction].
2005
[Results of application of synthetic antioxidants in treatment of patients with destructive pancreatitis].
2005
[Efficacy of emoxypine in combined therapy for elderly patients with postinfarct cardiosclerosis and heart failure].
2004
Patents

Patents

Sample Use Guides

Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:00:16 GMT 2025
Edited
by admin
on Mon Mar 31 19:00:16 GMT 2025
Record UNII
V247P5H4E1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EMOXYPINE
Common Name English
METHYLETHYLPIRIDINOL
WHO-DD  
Preferred Name English
EMOXYPIN
Common Name English
EMOXIPIN
Common Name English
EPIGID
Common Name English
2-ETHYL-6-METHYL-3-PYRIDINOL
Systematic Name English
EMOXIPINE
Common Name English
Methylethylpiridinol [WHO-DD]
Common Name English
ETHYLMETHYLHYDROXYPYRIDINE
Common Name English
3-PYRIDINOL, 2-ETHYL-6-METHYL-
Systematic Name English
6-METHYL-2-ETHYL-3-HYDROXYPYRIDINE
Systematic Name English
2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE
Systematic Name English
2-ETHYL-3-HYDROXY-6-METHYLPYRIDINE
Systematic Name English
EPYGID
Common Name English
Code System Code Type Description
FDA UNII
V247P5H4E1
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
EVMPD
SUB33006
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID40178313
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
MESH
C009820
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
CAS
2364-75-2
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
PUBCHEM
114681
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
SMS_ID
100000177536
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
WIKIPEDIA
EMOXYPINE
Created by admin on Mon Mar 31 19:00:16 GMT 2025 , Edited by admin on Mon Mar 31 19:00:16 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY